Physician profile
Taylor Sandmann
NPI 1134892300
$3,856.08
in general payments reported to CMS, 2019-2025
11 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.56 · 2023: $2,597 · 2024: $836 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,804 · Travel and Lodging: $924 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,804.21 |
| Travel and Lodging | $924.31 |
| Education | $112.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $1,343.00 | 2023 | Remede System |
| Jazz Pharmaceuticals INC. | $675.57 | 2023-2025 | |
| Axsome Therapeutics, INC. | $466.09 | 2023-2025 | Sunosi, Auvelity |
| Harmony Biosciences LLC | $462.28 | 2023-2025 | Wakix |
| Inspire Medical Systems, INC. | $415.32 | 2023-2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $356.34 | 2023-2024 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $57.76 | 2023-2025 | Lumryz |
| Novo Nordisk INC | $27.33 | 2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $20.96 | 2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $15.87 | 2023 | Belsomra |
| Alexion Pharmaceuticals, INC. | $15.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Sandmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.